The mutations of NRAS usually occur at G12, G13, and Q61 sites, and are found in around 25% of cases of melanomas.32 Compared to BRAFV600E mutation which can be effectively targeted by some agents like vemurafenib and dabrafenib, therapeutic options for melanoma harboring NRAS mutations lag behind. The gene discussed is NRAS; the disease is melanoma.